Dr. Scott Alpizar is a neuroscientist turned investor, operator, and now banker working at the intersection of life science innovation and capital formation. He focuses on helping early-stage companies navigate the gap between scientific discovery and scalable, fundable businesses.

He serves as a Life Sciences & Technology Advisor at Fulton Bank, where he supports innovative companies across NJ and Philadelphia that may be too early, technical, or unconventional for traditional banks with tailored financial solutions and strategic guidance. He works closely with founders, investors, and ecosystem partners to help companies navigate financing strategies, optimize their capital structure, and build long-term banking relationships.

In parallel, he is also the Founder and Managing Partner of Emerging Innovations Consulting, where he supports academic or scientist-led startups in raising non-dilutive and private capital, building investor-ready narratives, and advancing their technologies from concept to early traction. Previously, he worked at Foundation Venture Capital Group, where he led investments in academic spinouts and early-stage biotech companies. 

He is an Instructor for the NSF I-Corps Program, an Entrepreneur-in-Residence for multiple incubators and economic development programs, and serves as a mentor and advisor across leading innovation programs including Nucleate, Creative Destruction Lab, and Equalize. Finally, he is the CEO of Pinco Biotherapeutics, where he is developing a novel DNA-based therapy targeting chronic neuropathic pain.